Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
1. 请及时下载文件确认是否正确, 系统将在 2026-01-15 16:48:51 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
A Balasubramanian, C Marceaux, S Kanwal…
Clinical Cancer …, 2025
aacrjournals.org
Purpose: Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non–small cell lung cancers. There is an unmet need to improve outcomes for patients with this condition. Oncolytic viruses represent an attractive treatment approach because of their dual activity in inducing tumor cell lysis directly and potentially augmenting antitumor immunity. In this study, we present the safety, efficacy, and translational findings from a phase I/II single-arm trial utilizing CVA21, an oncolytic …
